U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H12NO2.Cl
Molecular Weight 153.607
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Betaine hydrochloride

SMILES

[Cl-].C[N+](C)(C)CC(O)=O

InChI

InChIKey=HOPSCVCBEOCPJZ-UHFFFAOYSA-N
InChI=1S/C5H11NO2.ClH/c1-6(2,3)4-5(7)8;/h4H2,1-3H3;1H

HIDE SMILES / InChI

Description

Betaine is a methyl derivative of glycine first isolated from the juice of sugar beets. Betaine is found in many common foods, but concentrated significantly in beets, spinach, wheat foods, and shellfish. In addition, betaine can be synthesized within the human body. Betaine participates in the methionine cycle, which produces vital biomolecules including proteins, hormones, phospholipids, polyamines, and nutrients. Betaine is used as a dietary supplement and has a beneficial effect on the human health. In the USA, FDA approved a betaine-containing drug Cystadane for the treatment of homocystinuria. The drug acts as a methyl group donor in the remethylation of homocysteine to methionine.

CNS Activity

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CYSTADANE

Cmax

ValueDoseCo-administeredAnalytePopulation
1.456 mM
50 mg/kg bw 2 times / day multiple, oral
BETAINE plasma
Homo sapiens
0.939 mM
50 mg/kg bw single, oral
BETAINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
12.528 mM × h
50 mg/kg bw 2 times / day multiple, oral
BETAINE plasma
Homo sapiens
5.518 mM × h
50 mg/kg bw single, oral
BETAINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
41.17 h
50 mg/kg bw 2 times / day multiple, oral
BETAINE plasma
Homo sapiens
14.38 h
50 mg/kg bw single, oral
BETAINE plasma
Homo sapiens

Doses

PubMed

Sample Use Guides

In Vivo Use Guide
The usual dosage in adult and pediatric patients is 6 grams per day administered orally in divided doses of 3 grams twice daily. In pediatric patients less than 3 years of age, dosage may be started at 100 mg/kg/day divided in twice daily doses, and then increased weekly by 50 mg/kg increments.
Route of Administration: Oral
In Vitro Use Guide
HeLa cells were treated with 0.1, 1.0, 5.0, 20.0, 100.0 mg/ml of betaine to evaluate the anticancer efficacy of the compound. The percentage of S phase cells in the low dose groups (< 5mg/ml) were distinctly higher than in high dose groups, and the rates of Sub-G1 phase were the opposite. A high concentration of betaine (>5.0mg/ml) significantly promoted the apoptosis of HeLa cells.